BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Cancer

...a synthetic analog of an endogenous adrenal steroid hormone that inhibits ERK-2 and NF-kB from Harbor BioSciences...
BioCentury | Mar 7, 2011
Clinical News

Harbor BioSciences, China National Pharmaceutical Group preclinical data

...Euronext:SAN; NYSE:SNY, Paris, France) markets Taxotere, while AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) markets Arimidex. Harbor BioSciences...
BioCentury | Feb 28, 2011
Clinical News

Harbor BioSciences preclinical data

...of an endogenous adrenal steroid hormone, has completed Phase IIa testing for Type II diabetes. Harbor BioSciences...
BioCentury | Feb 14, 2011
Clinical News

Apoptone: Phase I/IIa completed

...CIPI) subsidiary exclusive rights to develop and commercialize Apoptone in China (see BioCentury, Jan. 24). Harbor BioSciences...
BioCentury | Feb 7, 2011
Strategy

Networked in China

...Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs...
...Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Hainan Kaihua Pharmaceutical Co. Ltd. , Hainan, China Harbor BioSciences...
BioCentury | Jan 24, 2011
Company News

Harbor BioSciences, China National Pharmaceutical Group Corp. deal

...all preclinical and clinical data generated and is eligible to receive milestone payments and royalties. Harbor Biosciences...
BioCentury | Oct 4, 2010
Clinical News

Apoptone: Additional Phase I/IIa data

...15). Patients received 10-350 mg/day oral Apoptone in 28-day cycles until toxicity or disease progression. Harbor BioSciences...
BioCentury | Sep 27, 2010
Financial News

Harbor BioSciences financial update

...requirements. The company is now listed on the OTC Bulletin Board under the same symbol. Harbor BioSciences...
BioCentury | Jun 14, 2010
Financial News

Harbor BioSciences completes direct public offering

Harbor BioSciences Inc. (NASDAQ:HRBR), San Diego, Calif. Business: Endocrine, Autoimmune, Cancer Date completed: 6/7/10 Type: Direct public offering Raised: $2.1 million Units: 5.9 million Price: $0.35 (unit) Shares after offering: 35.4 million Placement agent: Chardan...
BioCentury | May 17, 2010
Clinical News

Triolex: Phase IIa data

...dose of metformin and the second stage enrolled 69 treatment-naïve patients. Triolex was well tolerated. Harbor BioSciences...
Items per page:
1 - 10 of 175
BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Cancer

...a synthetic analog of an endogenous adrenal steroid hormone that inhibits ERK-2 and NF-kB from Harbor BioSciences...
BioCentury | Mar 7, 2011
Clinical News

Harbor BioSciences, China National Pharmaceutical Group preclinical data

...Euronext:SAN; NYSE:SNY, Paris, France) markets Taxotere, while AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) markets Arimidex. Harbor BioSciences...
BioCentury | Feb 28, 2011
Clinical News

Harbor BioSciences preclinical data

...of an endogenous adrenal steroid hormone, has completed Phase IIa testing for Type II diabetes. Harbor BioSciences...
BioCentury | Feb 14, 2011
Clinical News

Apoptone: Phase I/IIa completed

...CIPI) subsidiary exclusive rights to develop and commercialize Apoptone in China (see BioCentury, Jan. 24). Harbor BioSciences...
BioCentury | Feb 7, 2011
Strategy

Networked in China

...Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs...
...Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Hainan Kaihua Pharmaceutical Co. Ltd. , Hainan, China Harbor BioSciences...
BioCentury | Jan 24, 2011
Company News

Harbor BioSciences, China National Pharmaceutical Group Corp. deal

...all preclinical and clinical data generated and is eligible to receive milestone payments and royalties. Harbor Biosciences...
BioCentury | Oct 4, 2010
Clinical News

Apoptone: Additional Phase I/IIa data

...15). Patients received 10-350 mg/day oral Apoptone in 28-day cycles until toxicity or disease progression. Harbor BioSciences...
BioCentury | Sep 27, 2010
Financial News

Harbor BioSciences financial update

...requirements. The company is now listed on the OTC Bulletin Board under the same symbol. Harbor BioSciences...
BioCentury | Jun 14, 2010
Financial News

Harbor BioSciences completes direct public offering

Harbor BioSciences Inc. (NASDAQ:HRBR), San Diego, Calif. Business: Endocrine, Autoimmune, Cancer Date completed: 6/7/10 Type: Direct public offering Raised: $2.1 million Units: 5.9 million Price: $0.35 (unit) Shares after offering: 35.4 million Placement agent: Chardan...
BioCentury | May 17, 2010
Clinical News

Triolex: Phase IIa data

...dose of metformin and the second stage enrolled 69 treatment-naïve patients. Triolex was well tolerated. Harbor BioSciences...
Items per page:
1 - 10 of 175